Tiziana Life Sciences’ Alzheimer’s treatment validated in new study
–News Direct– Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced the publication of a new study into the potential use of its Foralumab nasal spray as a treatment for Alzheimer's disease. David explains that the study has been published in the Proceedings of the National Academy of Science (PNAS) journal and demonstrated significant improvements in Alzheimer's-related factors independent of amyloid beta and
Read more